Tag: Target validation

Approximately 9 out of 10 drug candidates fail during clinical trials, often due to a lack of clinical efficacy or unexpected toxicity, making correct **what is a target identifier?** a cornerstone of successful drug development. Identifying the right molecular target early is a critical step that significantly reduces risk and cost in the pharmaceutical industry.

Estimates suggest that only about 22% of the 20,300 protein-coding genes in the human genome are considered 'druggable' [1.4.3]. The critical question for researchers is, within this vast biological landscape, **what makes a druggable target** and sets the stage for a new therapeutic intervention?

According to the National Institutes of Health, while the human genome contains approximately 4,500 genes considered part of the 'druggable genome', existing clinical drugs target only a few hundred of these. Therefore, understanding **what is target identification in druggable** is a critical first step in discovering new medications and unlocking the full potential of these untapped targets.

An estimated 90% of drugs that enter clinical trials ultimately fail, with a significant portion of these failures attributed to a lack of efficacy [1.6.3]. This staggering statistic underscores a foundational question in pharmacology: how do you identify a drug target that leads to a successful therapy?